Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
07 Agosto 2023 - 7:30AM
Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty
pharmaceutical company focused primarily on treatments for
gastrointestinal (GI) diseases with an emphasis on
GIMOTI® (metoclopramide) nasal spray,
and EVERSANA™, a leading provider of global commercial
services to the life science industry, announced that its
abstract entitled “Nasal Metoclopramide Reduces Healthcare Visits
in Diabetic Gastroparesis Patients With and Without Prior Oral
Metoclopramide History” will be presented in a poster session at
the American Neurogastroenterology and Motility Society (ANMS)
Annual Meeting being held August 11-13, 2023 in Austin, Texas.
During the meeting, David C. Kunkel, MD, Gastroenterologist and
Associate Professor of Medicine at the University of California San
Diego (UCSD) Health and lead author, will present data from a
retrospective real-world evidence analysis of 294 patients
receiving nasal metoclopramide (GIMOTI) and their associated
healthcare resource utilization usage (ER visits, physician office,
outpatient facility, etc.) in patients who either had prior
treatment with oral metoclopramide or patients that were oral
metoclopramide-naïve. The study was designed to evaluate whether
GIMOTI, the only FDA approved nasal metoclopramide treatment for
acute and recurrent diabetic gastroparesis, reduced the need for
doctor’s office, emergency department, inpatient, and outpatient
visits across all settings for patients using GIMOTI versus the
prior period in the two groups.
Dr. David C. Kunkel, the lead author, commented, “Earlier this
year, we had the privilege of presenting compelling data on the
reduction in healthcare resource utilization at another esteemed
gastroenterology conference. I am honored to bring these additional
insights on the merits of nasal metoclopramide to the ANMS
community. As the first non-oral outpatient treatment for diabetic
gastroparesis, GIMOTI presents a unique and effective option for
patient care. Our research clearly demonstrates its positive impact
across healthcare settings, benefiting both patients and providers.
It’s a significant step forward in our continuous endeavor to
enhance treatment for this debilitating condition.”
“As Evoke continues to advance and support innovations in the
field of gastroenterology, we pay critical attention to healthcare
provider and patient experiences in relation to GIMOTI. The
consecutive acknowledgments of this Real-World data at conferences
including ANMS attest to its significance in the GI arena. We are
grateful for the efforts Dr. Kunkel and other key opinion leaders
put into producing such ground breaking and industry leading
research,” commented David Gonyer, R.Ph., Chief Executive Officer
of Evoke Pharma.
The announcement of these data correspond with Gastroparesis
Awareness Month, which is observed every August to raise focused
attention on important health messages about gastroparesis
diagnosis, treatment, and quality of life issues, all in an effort
to improve patient care. We want to thank the providers and
patients who trusted GIMOTI as part of their treatment regimen,
without whom we could not have generated these important data and
insights. A major element of support of Gastroparesis Awareness
Month this year is using the data gathered to challenge
stakeholders on how to think differently about improving the life
of the millions of patients seeking treatment for gastroparesis.
Further, EVERSANA Intouch has made a financial donation to IFFGD,
on behalf Evoke and our GIMOTI collaboration.
Details of the poster session are as follows:
Title: Nasal Metoclopramide Reduces Healthcare Visits in
Diabetic Gastroparesis Patients With and Without Prior Oral
Metoclopramide History
Presentation Date/Time: Saturday, August 12, 2023, at 12:30pm
CT
Poster Number: 126
Location: Fairmont Hotel, Austin, Texas
About Evoke Pharma, Inc.Evoke is a
specialty pharmaceutical company focused primarily on the
development of drugs to treat GI disorders and diseases. The
company developed, commercialized and markets GIMOTI, a nasal spray
formulation of metoclopramide, for the relief of symptoms
associated with acute and recurrent diabetic gastroparesis in
adults. Diabetic gastroparesis is a GI disorder affecting millions
of patients worldwide, in which the stomach takes too long to empty
its contents resulting in serious GI symptoms as well as other
systemic complications. The gastric delay caused by gastroparesis
can compromise absorption of orally administered medications. Prior
to FDA approval to commercially market GIMOTI, metoclopramide was
only available in oral and injectable formulations and remains the
only drug currently approved in the United States to
treat gastroparesis.
Visit www.EvokePharma.com for more information.Follow
GIMOTI on FacebookFollow Evoke
Pharma on FacebookFollow Evoke
Pharma on LinkedInFollow Evoke
Pharma on Twitter
About EVERSANAEVERSANA® is a leading
independent provider of global services to the life sciences
industry. The company’s integrated solutions are rooted in the
patient experience and span all stages of the product life cycle to
deliver long-term, sustainable value for patients, prescribers,
channel partners and payers. The company serves more than 650
organizations, including innovative start-ups and established
pharmaceutical companies, to advance life sciences solutions for a
healthier world. To learn more about EVERSANA,
visit eversana.com or connect
through LinkedIn and Twitter.
Safe Harbor StatementEvoke cautions you that
statements included in this press release that are not a
description of historical facts are forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negatives
of these terms or other similar expressions. These statements are
based on the company’s current beliefs and expectations. These
forward-looking statements include statements regarding: GIMOTI’s
potential to reduce healthcare resource utilization by diabetic
gastroparesis patents; and Evoke’s belief that GIMOTI can improve
treatment of diabetic gastroparesis. The inclusion of
forward-looking statements should not be regarded as a
representation by Evoke that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Evoke’s
business, including, without limitation: Evoke’s and EVERSANA’s
ability to successfully drive market demand for GIMOTI; Evoke’s
ability to obtain, maintain and successfully enforce intellectual
property protection for GIMOTI; the results of market research
studies may not predict acceptance by patients, healthcare
providers or payors; inadequate efficacy or unexpected adverse side
effects relating to GIMOTI that could result in recalls or product
liability claims; Evoke’s ability to obtain additional financing as
needed to support its operations; Evoke is entirely dependent on
the success of GIMOTI; Evoke’s dependence on third parties for the
manufacture of GIMOTI; and other risks and uncertainties detailed
in Evoke’s prior press releases and in the periodic reports it
files with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Evoke
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995.
Investor Contact:Daniel Kontoh-BoatengDKB
PartnersTel: 862-213-1398dboateng@dkbpartners.net
Evoke Pharma (NASDAQ:EVOK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Evoke Pharma (NASDAQ:EVOK)
Gráfica de Acción Histórica
De May 2023 a May 2024